



PRIMARY CARE CONFERENCES
EXCEPTIONAL CME | EXTRAORDINARY LOCATIONS

WWW.MER.ORG

INTERNAL MEDICINE FOR PRIMARY CARE: CANNABIS/NEUROLOGY/PALLIATIVE/ RHEUMATOLOGY

**Walt Disney World® Resort, FL - Disney's Grand Floridian Resort & Spa
March 21 - 25, 2027**

Sunday, March 21, 2027

2:30 pm

Check-In

3:00 pm - 4:00 pm - Neurology

Evaluating Weakness

Using the history and physical examination to distinguish weakness from non-specific symptoms; characteristics of neurological diseases that produce weakness; presentations of representative diseases of the nervous system

4:00 pm - 5:00 pm - Neurology

Alzheimer's & Other Dementias

Review changes in cognition with normal aging; Behavioral changes that may precede early dementia; Screening tools for dementia; Characteristics of different dementia syndromes; Risks and benefits for treatment of Alzheimer Disease; Risk factors and causes of delirium, and how to reduce them; How to suspect and identify delirium; Management of the symptoms of delirium; Distinguishing delirium from dementia

5:00 pm - 6:00 pm - Neurology

Parkinson's Disease & Other Movement Disorders

Epidemiology; cardinal features; secondary features; pathology; neurochemistry; differential diagnosis; treatment; complication; other movement disorders; neuroleptic- induced movement disorders; chorea

6:00 pm

Session Adjourns

Monday, March 22, 2027

7:00 am

Arrival and Breakfast

7:30 am - 8:30 am - Cannabis

The Science Behind the Endocannabinoid System

Discussion of the endocannabinoid system and how it interacts in various organ systems; Discussion of how the endocannabinoid and opioid systems interact; Discussion will demonstrate the various drug interactions exogenous cannabinoids may have on the human body

8:30 am - 9:30 am - Cannabis

The Brain on Cannabis: Addiction, Depression, Psychosis, and More

The brain as the target organ in the use of cannabis; Description of the impacts on the brain, including anxiety, depression, suicidality, and psychosis; The biological mechanisms of these impacts will be outlined

9:30 am - 9:40 am

Coffee Break

9:40 am - 10:40 am - Cannabis

The Heart on Cannabis: Short and Long-Term Risks

The heart as the second most important targeted organ by the endocannabinoid system; Demonstration of the mechanisms and highlights of the importance of screening for cannabis use, particularly in younger people; Examples of the cardiac impacts

10:40 am - 11:40 am - Neurology

Migraine Headaches

Diagnosis based on headache history; Classification and pathophysiology of migraine; Acute migraine treatment; Prophylaxis for recurrent migraine attacks; Chronic migraine, tension-type headaches, and cluster headaches; Trigeminal Neuralgia

11:40 am - 12:40 pm - Neurology

Peripheral Neuropathy and Neuropathic Pain

Discussion of the spectrum of neuropathic signs, symptoms and causes; the approach to bedside examination; discussion of the mechanism of neuropathic pain; effective therapies

12:40 pm

Session Adjourns

Tuesday, March 23, 2027

7:00 am

Arrival and Breakfast

7:30 am - 8:30 am - Rheumatology

Update in Pharmacology for Arthritis

Review risks and benefits of traditional NSAIDs and cox-2 inhibitors; Analgesics (narcotics and tramadol), acetaminophen, conventional-synthetic DMARDs, and bDMARDs

8:30 am - 9:30 am - Rheumatology

Osteoarthritis

Pathogenesis, diagnosis and treatment

9:30 am - 9:40 am

Coffee Break

9:40 am - 10:40 am - Rheumatology

Differential Diagnosis of Inflammatory Arthritis

Clinical presentation and laboratory work-up and treatment for rheumatoid arthritis, systemic lupus erythematosus, spondyloarthropathies (SPA), infectious arthritis and systemic sclerosis; Treatment of RA with DMARDs; Treatment principles of SLE, Sjogren's, SPA and PMR

10:40 am - 11:40 am - Cannabis

Exposure to Cannabis In Vulnerable Populations

Discussion of the impact of cannabis use on vulnerable populations; Inclusion of in utero effects and the effects on young children as well as the elderly; tips for providers in conversations with patients, parents, and family members

11:40 am - 12:40 pm - Cannabis

Medical Harms of Cannabinoids

There is a growing literature base that describes the adverse consequences of cannabinoid use on multiple organ systems. This lecture will address a variety of these cannabinoid induced syndromes including the effects of prenatal cannabinoid use.

12:40 pm

Session Adjourns

Wednesday, March 24, 2027

7:00 am

Arrival and Breakfast

7:30 am - 8:30 am - Palliative

Medicare Hospice Benefit

Which patients are eligible? What is palliative care? What does the Medicare benefit provide for patients and families?

8:30 am - 9:30 am - Palliative

Palliative Care for the PCP: Symptom Management

Symptom management; Symptom management of dyspnea and cough, pain, nausea and vomiting, constipation, and agitation, at the end of life

9:30 am - 9:40 am

Coffee Break

9:40 am - 10:40 am - Palliative

Prognostication for the PCP

Estimating life expectancy for patients with life-limiting illnesses such as CHF, Alzheimer's dementia, Parkinson's disease, end stage renal disease

10:40 am - 11:40 am - Rheumatology

Osteoporosis

Review the epidemiology and pathophysiology of osteoporosis along with interpretation of DEXA scans and FRAX risk assessment; up-to-date therapeutic options

11:40 am - 12:40 pm - Rheumatology

Crystal Disease: Gout & Pseudogout

Properly diagnosing and treating crystal diseases such as gout and pseudogout

12:40 pm

Session Adjourns



Thursday, March 25, 2027

7:00 am

Arrival and Breakfast

7:30 am - 8:30 am - Palliative

Addressing Goals of Care

Definition of POA, DNR, DNI, DNH, MOLST, POLST; Techniques on how to address goals of care, both in acute crisis as well as when the patient has chronic issues

8:30 am - 9:30 am - Palliative

Pain Management in the Palliative Care Patient

Treatment of pain with both nonopioid and opioid medications; New guidelines related to opioid prescribing; Side effects management

9:30 am

Conference Adjourns

Target Audience

This program is targeted to office-based primary care providers and other health professionals with updates in primary care medicine

Learning Objectives

Upon completion of this program, participants should be better able to:

- Utilize history and physical examination to distinguish weakness from non-specific symptoms
- Discuss evidence-based management options for Alzheimer's disease
- Evaluate weakness and recognize cardinal features of Parkinson's disease as well as other movement disorders
- Describe the differential diagnosis and treatment options for migraine headaches
- Discuss the mechanism of neuropathic pain
- Describe the effects the endocannabinoid and opioid systems have on the body
- List ways cannabis impacts a patient's brain activity
- Demonstrate an understanding of the cardiac impacts by cannabinoids
- Discuss the impacts of cannabis on the adolescent, in utero and the elderly
- Discuss the adverse consequences of cannabinoid use.
- Review the risks and benefits of the treatment options for arthritis (non-selective NSAIDs, cox-2 inhibitors, DMARDs, narcotics and tramadol)
- Utilize current evidence to design treatment strategies for osteoarthritis
- Describe the differential diagnoses of inflammatory arthritis based on clinical presentation and laboratory workup
- Identify the risks and benefits of utilizing bisphosphonates in the treatment of osteoporosis
- Diagnose and treat gout and pseudogout
- List details about the Medicare hospice benefit
- Describe the primary care approach to palliative medicine including symptom management
- Recognize the importance of prognosis in decision making for seriously ill patients
- Define and establish goals of care with patients and their families
- Discuss pain management options with both nonopioid and opioid medications

Disclosure of Relevant Financial Relationships

Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. All relevant financial relationships have been mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in healthcare, and not the business interests of an ineligible company.

Disclaimer

The content, views and opinions presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Accreditation Statements

Joint Accreditation for Interprofessional Continuing Education



In support of improving patient care, Medical Education Resources is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 20 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physician Credit Designation

AMA PRA Category 1 Credits™

Medical Education Resources designates this live activity for a maximum of 20 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine MOC Recognition (ABIM)



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 20 (part II) MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Academy of Family Physicians (AAFP)

AAFP has reviewed Internal Medicine for Primary Care: Cannabis/Neuro/Rad/Rheum and deemed it acceptable for up to 20.00 Live AAFP Prescribed credit(s). Term of approval is from 3/21/2027 to 3/25/2027. Physicians should claim only the credit commensurate with the extent of the their participation in the activity.

American Osteopathic Association (AOA)

These programs are approved for 20 hours in Category 2-A by the American Osteopathic Association.

American College of Emergency Physicians (ACEP)

This program is approved by the American College of Emergency Physicians for a maximum of 20 hours of ACEP Category I credit.

Canadian Physicians

The American Academy of Family Physicians (AAFP) and the College of Family Physicians of Canada (CFPC) have a bilateral reciprocal certification agreement whereby: CME/CPD activities held across the Canada - U.S. border are certified according to the nationality of the primary target audiences regardless of where the providers are located. The activities will be reviewed according

to the criteria of the certifying organization.

Nursing Credit Designation

American Nurses Credentialing Center (ANCC)

Medical Education Resources designates this live activity for a maximum of 20 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.

This activity is designated for 9.25 ANCC pharmacotherapeutic contact hours.

American Academy of Nurse Practitioners (AANP)

The American Academy of Nurse Practitioners (AANP) Certification Board recognizes and accepts continuing education (CE) contact hours from activities approved by AMA, ACCME, ANCC, AANP, AAFP and AACN.

California Board of Registered Nursing

Medical Education Resources is approved by the California Board of Registered Nursing, Provider Number 12299, for 20 contact hours.

Physician Associates Credit Designation

American Academy of Physician Associates (AAPA)



Medical Education Resources has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 20 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Pharmacy Accreditation

Accreditation Council for Pharmacy Education (ACPE)



Medical Education Resources (MER) designates this live continuing education activity for 20 contact hours (2.0 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Program Number: JA0003680-0000-21-XXX-L01-P

Participants will be required to sign in at the start of the program and/or complete a program evaluation.

Credits will be uploaded into CPE Monitor within 60 days of the activity.

This activity is certified as Knowledge-based CPE.